NOTICE OF THE ANNUAL GENERAL MEETING 2024 OF AMBU A/S
8.11.2024 12:15:29 CET | Ambu A/S | Notice to general meeting
Notice is hereby given of the annual general meeting of Ambu A/S, CVR no. 63 64 49 19, which is held on
Wednesday, 4 December 2024 at 1:00 pm (CET)
at the company's address at Baltorpbakken 13, 2750 Ballerup.
Board of Directors
The Board of Directors proposes re-election of Jørgen Jensen as Chair of the Board and Shacey Petrovic as Vice Chair.
The Board of Directors proposes that Susanne Larsson, Michael del Prado and Simon Hesse Hoffmann are all re-elected.
Furthermore, the Board of Directors proposes that David Hale be elected as a new member to the Board of Directors.
Christian Sagild has decided not to run for re-election.
The notice for this year's annual general meeting, including information about the proposed Board candidates, is enclosed. This notice is available in Danish and English-language versions. In the event of discrepancies, the English version shall prevail.
Ambu A/S offers the possibility of viewing the annual general meeting 2024 via live webcast on Ambu's website. Please refer to the notice for further information.
Contacts
Anders Hjort, Head of Investor Relations, +45 2892 8881, anhj@ambu.com
Tine Bjørn Schmidt, Head of Corporate Communications, +45 2264 0697, tisc@ambu.com
About Ambu A/S
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 5,000 people in Europe, North America, Latin America and Asia Pacific.
For more information, please visit Ambu.com.
Attachments:
Download announcement as PDF.pdf
Indkaldelse til ordinr generalforsamling 2024 i Ambu A-S - Selskabsmeddelelse nr. 5 2024-25.pdf
Notice of annual general meeting 2024 of Ambu A-S - Company announcement no 5 2024-25.pdf
This news release was distributed by Company News System, www.nasdaqomxnordic.com/news/marketnotices To subscribe on regulatory news from this company, go to the subscription page
Attachments
Original document
Permalink
Disclaimer
Ambu A/S published this content on November 08, 2024, and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on November 08, 2024 at 11:42:14.526.
Ambu A/S is specialized in the design, production and marketing of medical supplies. Net sales break down by family of products as follows:
- single-use endoscopes (59.2%);
- emergency care and resuscitation devices (21.4%): mechanical ventilation devices (insufflators, laryngeal masks, facial masks and respiratory bags), secretion aspirators, immobilization devices, etc. In addition, the group sells dummies for first aid training centers;
- monitoring and diagnostic devices (19.4%): including electrodes used in the fields of cardiology, neurophysiology and first aid.
At the end of September 2024, Ambu A/S had four production sites located in China, Malaysia, the United States and Mexico.
Net sales are distributed geographically as follows: Denmark (1.1%), Europe (38.1%), the United States (49.5%), North America (1.2%) and other (10.1%).
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
